Choosing A CDMO That Can Grow With A Viral Program

By Kai Lipinski, Ph.D. Chief Scientific Officer, Recipharm Advanced Bio

Viral vectors, vaccines, and oncolytic viruses are far less standardized than mature biologics platforms, which raises the stakes on familiar CDMO criteria such as quality, capacity, and track record.

The question shifts from whether a provider can run the process today to whether it can manage the transitions ahead: new equipment, larger scale, qualified assays, and GMP requirements. Written by Dr. Lipinski, Chief Scientific Officer at Recipharm Advanced Bio, this paper considers how to judge experience by relevance rather than volume, why analytical development belongs in the manufacturing fit assessment, and how to separate capabilities required now from those a CDMO can credibly build.

Explore the framework before your next RFP.